You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黄医药治疗晚期结直肠癌药获纳入新版国家医保药品目录
阿思达克 12-10 11:30

长和(00001.HK)公布,旗下和黄医药用於治疗晚期结直肠癌的国家 1类创新标靶抗癌药物爱优特,已获纳入医保局公布的新版国家医保药品目录,其可及性将延展至内地所有省份,并将於2020年1月1日开始,在各大公立医院药房上架。

爱优特是次获纳入医保药品目录,标志着和黄医药将进一步提升爱优特在内地市场的覆盖和可及性。

爱优特是和黄医药在内地上市的首款抗肿瘤新药,同时是抗肿瘤治疗主流领域首个从发现、研发到无附加条件获批均在中国完成的药物。自2018年11月推出市场以来,已累计帮助了数千名患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account